Literature DB >> 15273424

Combination therapy with angiotensin-converting enzyme inhibitor and oral adsorbent of uremic toxins can delay the appearance of glomerular sclerosis and interstitial fibrosis in established renal failure.

Kazuyoshi Okada1, Erina Okawa, Hiroshi Shibahara, Takashi Maruyama, Noriaki Maruyama, Koichi Matsumoto, Susumu Takahashi.   

Abstract

BACKGROUND/AIM: Angiotensin II plays a central role in the progression of chronic renal failure (CRF), and administration of angiotensin-converting enzyme inhibitor (ACEI) in rats delays the progression of CRF. However, ACEI has little effect on CRF progression in rats with established CRF. We therefore examined whether combination therapy with ACEI and oral adsorbent for uremic toxins in the gastrointestinal tract has the desired effect.
METHODS: Rats subjected to subtotal nephrectomy were given enalapril at 20 mg/kg (n = 10, group E), AST-120 at 5 g (n = 10, group A), enalapril and AST-120 together at the same doses (n = 10, group EA), or no treatment (n = 10, group C) 8 weeks after the operation. The substances were administered in 100 g rat chow. All animals were pair-fed, and all were killed after 8 weeks of pair-feeding.
RESULTS: Body weight did not differ between groups during the study. Blood pressure at week 8 was significantly lower in groups E and EA than in groups C and A (p < 0.05). Urinary protein excretion level and renal plasma flow rate at week 8 were significantly less in groups E and EA than in group C (p < 0.05, p < 0.01). The glomerular filtration rate at week 8 was significantly higher in group EA than in group C (p < 0.05). The glomerular sclerosis index and interstitial fibrosis area at week 8 were significantly less in group EA than in group C (p < 0.01).
CONCLUSION: ACEI and AST-120 in combination can delay progression of established CRF in rats by inhibiting the appearance of glomerular sclerosis and interstitial fibrosis. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15273424     DOI: 10.1159/000079869

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  3 in total

1.  NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy.

Authors:  Philipp Kalk; Michael Godes; Katharina Relle; Christiane Rothkegel; Andreas Hucke; Johannes-Peter Stasch; Berthold Hocher
Journal:  Br J Pharmacol       Date:  2006-06-12       Impact factor: 8.739

2.  Mineralocorticoid Receptor Blocker Protects against Podocyte-Dependent Glomerulosclerosis.

Authors:  Nobuaki Takagi; Takakuni Tanizawa; Valentina Kon; Agnes B Fogo; Iekuni Ichikawa; Ji Ma
Journal:  Nephron Extra       Date:  2012-01-31

3.  Effects and Safety of an Oral Adsorbent on Chronic Kidney Disease Progression: A Systematic Review and Meta-Analysis.

Authors:  Ying-Chun Chen; Mei-Yi Wu; Ping-Jen Hu; Tzu-Ting Chen; Wan-Chen Shen; Wei-Chiao Chang; Mai-Szu Wu
Journal:  J Clin Med       Date:  2019-10-17       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.